Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

Summary

Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine, Liposomal Bupivicaine or regional nerve block for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds.

Timeline

Start

2019-03-18

Primary completion

2025-08-06

Completion

2025-10-27

Outcome

Missed primary endpoint

paper There were no statistical differences in pain scores at any time point postoperatively PMID 34216466 ↗

paper There were no statistical differences in opioid consumption at 24, 48, or 72 h postoperatively between the groups PMID 34216466 ↗

Publications

• Egan KG, Guest R, Sinik LM, Nazir N, De Ruyter M, Ponnuru S, Bhavsar D. Evaluation of Liposomal Bupivacaine at Split-Thickness Skin Graft Donor Sites Through a Randomized, Controlled Trial. J Burn Care Res. 2021 Nov 24;42(6):1280-1285. doi: 10.1093/jbcr/irab129.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupivacaine	Other / unclassified	266 mg	Subcutaneous
Subject	Bupivacaine	Other / unclassified	—	—
Comparator	Lidocaine	Other / unclassified	50 mg	Subcutaneous

Indications